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Introduction: Uterine leiomyosarcoma is one of the most frequent uterine sarcomas. In the metastatic setting it is
sensitive to doxorubicin, ifosfamide, gemcitabine, docetaxel and a few other drugs, but time to progression is
generally short. For this reason prognosis is often poor and there are few reports in the literature of long
responders.
Case presentation: We report a case of a 40-year-old Caucasian woman with metastatic uterine leiomyosarcoma
who began treatment six years before the presentation of this case report and for the following six years
underwent ten lines of chemotherapy, achieving excellent results and a good quality of life. Among the treatments
administered we observed a long response to temolozomide, an unconventional drug for this kind of disease.
Conclusion: Although there are few chemotherapeutic options for the management of metastatic uterine
leiomyosarcoma, a small number of patients have an unexpected long lasting response to treatment. For this
reason further research is needed to identify new therapeutic agents and the predictive factors for the achievement
of response.
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Uterine sarcomas are rare tumors with a poor prognosis;
they represent less than 3% of all female genital tract ma-
lignancies and only 8.4% of uterine cancers [1,2]. They can
be classified into two groups: smooth muscle tumors and
endometrial stromal tumors. The first group includes be-
nign leiomyomas, smooth muscle tumors of uncertain
malignant potential, and leiomyosarcomas (LMS). The se-
cond group is composed of benign endometrial stromal
nodules, endometrial stromal sarcomas and undifferenti-
ated endometrial sarcomas [1].
Treatment for early-stage disease is surgery, with to-
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reproduction in any medium, provided the orsalpingo-oophorectomy. The role of adjuvant chemo-
therapy or local radiotherapy is still controversial [1-3].
In the metastatic setting, treatment of a uterine sar-
coma includes resection of metastases, chemotherapy,
hormone therapy and targeted therapy [1,3,4]. Among
the chemotherapies used, the drugs that have shown the
best results are doxorubicin with or without ifosfamide,
gemcitabine and docetaxel and, more recently, trabec-
tedin and pazopanib [1,4-7]. Although literature data
underline the possibility of a long lasting response to
different types of therapy using drug associations, few
papers report encouraging results beyond second-line
chemotherapy.
We describe a case of a long-term responder to a wide
variety of drugs, highlighting that it is possible to offer
more than two lines of chemotherapy to some patients.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 40-year-old premenopausal Caucasian woman without
comorbidities underwent surgical treatment seven years
before the presentation of this case report for a clinical
diagnosis of uterine myoma. The postoperative histo-
logical examination revealed the presence of a LMS and
a hysterectomy with lymphadenectomy was thus perfor-
med. The tumor was estrogen and progesterone receptor
positive. A staging computed tomography scan detected
bilateral, multiple lung metastases of about four to six
mm. Six years before the presentation of this case re-
port the patient underwent first-line chemotherapy with
AdriamycinW (doxorubicin) and ifosfamide but after six
cycles of therapy the lung metastases had increased in
size and a new lesion had appeared in the abdomen near
the right psoas muscle. It was decided to perform a par-
tial resection of the lung metastases (with histological
confirmation) and an ovariectomy.
Second-line treatment with sorafenib was begun but
was rapidly discontinued because of toxicity and treat-
ment with dacarbazine was started as third-line. After
three cycles, progression in the lung metastases was
detected and continuous infusion of ifosfamide was
administered as fourth-line therapy for the following
two months. Then the patient was discharged from a
National Oncologic Centre to be treated with pallia-
tive care.
When the patient arrived in our Department, further
progression in the abdomen and chest caused an inabil-
ity to walk due to nerve impingement and pain and a
fifth-line of treatment was begun with docetaxel and
gemcitabine. In these 11 months the patient showed a
partial response and regained the ability to walk. Disease
stabilization in the following six months was achieved
with anastrozole (sixth line) and at the next progression
the patient was treated with paclitaxel and liposomal
doxorubicin (seventh line) for 19 cycles and then with
trabectedin (eighth line) for eight cycles, until May of
two years before the presentation of this case report. It
is noteworthy that more than four years had passed
since the initial diagnosis and the patient continued to
feel well (with only right leg pain, and three points on
visual analogue scale, VAS). After eight cycles of trabec-
tedin the lung metastases and pelvic lesion increased to
three cm and 18cm, respectively, causing bilateral ureteral
compression and an increase in leg pain (VAS eight
to nine).
In July of two years before the presentation of this case
report the patient’s performance status (PS) was two on
the Eastern Cooperative Oncology Group (ECOG) scale
and a bilateral nephrostomy was performed. A ninth-line
of treatment was started with temozolomide at a dose of
150mg/m2/day for five days every four weeks. Despite the
negative status of O6-methylguanine-deoxyribonucleicacid (DNA)-methyltransferase promoter methylation (this
kind of test is performed for patients with glioblastoma
multiforme to predict response to temozolomide [8]), a
rapid response to therapy was observed with a reduction
in the pelvic lesion, resolution of pain and removal of the
nephrostomies (Figures 1 and 2). The patient returned to
her normal life and was able to use her bicycle and to per-
form activities without leg pain or fatigue (ECOG PS 0)
that would previously have been unthinkable. Treatment
with temozolomide was completed after 24 months, with
very good tolerance, but further progression was detected.
The patient recently began a new line of therapy (the
tenth) with pazopanib and is currently doing well, six
years after the start of treatment.
Discussion
Our case underlines the role of conventional and un-
conventional drugs for the treatment of metastatic LMS.
Temozolomide has been tested in numerous clinical trials
on metastatic soft tissue sarcomas (STSs).
In 2011, Penel et al. [9] reported their analysis of new
regimens used in patients with STSs during the past 10
years and temozolomide at a dose of 75 to 100mg/m2/
day was considered a ‘promising drug’.
The Soft Tissue and Bone Sarcoma Group of the
European Organization for Research and Treatment of
Cancer [10] evaluated the use of 750mg/m2 of oral te-
mozolomide divided over five days every four weeks in
31 patients with advanced STSs. One partial response
for eight cycles was observed in a patient with retroperi-
toneal LMS metastatic to breast, skin, and liver. Nine
patients of varying histologies had stable disease, and 21
patients progressed to therapy. Nausea and vomiting were
the most commonly reported non-hematologic adverse
events; there were no episodes of neutropenic fever or
grade three or four hematologic toxicity.
Talbot et al. [11] treated 25 patients with STSs with
twice daily temozolomide for five days every four weeks.
Two patients had partial responses (8%), three patients
(12%) experienced stable disease for over six months,
and two patients had mixed responses (8%). All of these
responding patients had LMS. No treatment-related
deaths or grade four toxicity were observed.
In their study Trent et al. [12] evaluated patients with
gastrointestinal stromal tumors (GIST) and other STSs
treated with temozolomide at a dose of 85mg/m2/day
for 21 days followed by seven days of rest. Among 39
evaluable patients with non-GIST tumors, 18 had meta-
static LMS. Two responses (11%) were observed in the
other STSs subgroup and stable disease was observed in
33% of patients. One partial response lasting for seven
months was seen in a patient with metastatic pelvic
LMS to the lung. Grade three or four hematologic toxicity
was experienced in 10% of patients. The most common
Figure 1 Effect of temozolomide on pelvic metastasis. A: before the beginning of treatment. B: after 11 months of treatment.
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observed in 14% of patients.
Garcia del Muro et al. [13] evaluated oral temozolo-
mide given at 75mg/m2/day for six weeks in 43 patients
with STSs and 18 patients with GIST. In the first group,
seven patients obtained a partial response, eight patientshad stable disease and 28 patients had progressive dis-
ease. Responses were seen in five of the 11 patients who
had gynecologic LMS. The median duration of response
was 12.5 months. Severe hematological toxicities for the
61 patients of two groups were grade three or four gran-
ulocytopenia or thrombocytopenia (nine patients), grade
Figure 2 Effect of temozolomide on one of the lung metastases. A: before the beginning of treatment. B: after 11 months of treatment.
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four anemia (seven patients). Non-hematologic toxicity
was represented by nausea and vomiting (34 patients)
and fatigue (35 patients). No toxic deaths or episodes of
febrile neutropenia occurred.
Anderson and Aghajanian [14] evaluated patients with
advanced LMS treated with temozolomide at a dose of
50 to 75mg/m2/day for six weeks followed by a two-week
rest or temozolomide at a dose of 150 to 300mg/m2/day
for five days every four weeks. Among 12 patients treated
with continuous low-dose temozolomide, one patient hada partial response and the duration was four months, four
patients demonstrated stable disease and seven patients
progressed while on therapy. Among seven patients trea-
ted with bolus-dose temozolomide, one patient had a near
complete response, four patients experienced stable dis-
ease and two patients progressed while on therapy. There
were no toxicity-associated admissions, deaths, neutro-
penia or neutropenic fever for either dosing schedule.
On the basis of these works we decided to start the
treatment with temozolomide and in our patient it ob-
tained the best response and gave a good quality of life
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be considered after failure of standard treatment options.
Conclusion
This case report highlights the fact that some patients
with uterine LMS can have an exceptionally good res-
ponse to chemotherapy. On the basis of our experience
temozolomide should be used in these patients.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
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